-
Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2
prnewswire
August 05, 2021
Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection
-
Bio-Techne, Kantaro Biosciences to Launch Quantitative Research Use Only COVID-19 Serology Test
americanpharmaceuticalreview
August 11, 2020
Bio-Techne and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences, announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit.
-
Elpiscience, Bio-Techne to develop anti-cancer therapeutics
biospectrumasia
April 23, 2019
Elpiscience BioPharma and Bio-Techne Corporation have announced that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics.
-
Bio-Techne, Elpiscience Enter Strategic Anti-Cancer Alliance
b3cnewswire
April 23, 2019
Elpiscience will have access to multiple antibodies from Bio-Techne's product portfolio for use in the development of biopharmaceuticals...
-
Bio-Techne to acquire Exosome Diagnostics
biospectrumasia
June 27, 2018
The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.
-
Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tr
biospace
March 15, 2018
Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface
-
Bio-Techne introduces Zika virus detection assay
biospectrumasia
September 13, 2017
The kit can also be used to detect any previous infections and identify if the virus might lead to subsequent neurological disorders or foetal abnormalities.